Treatments

*January 2020* Dana-Farber’s Pasi Jänne, MD, PhD, and his colleagues say they have discovered a mechanism within lung cancer cells that enables the cells to lie dormant and avoid destruction by the cancer drugs. Read more.

*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib has shown promise for the treatment of this patient population, according…

*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the Ministry of Food and Drug Safety (MFDS) in Korea to initiate…

*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to two randomized trials. A phase III trial from India showed that median PFS increased from 8 months with the EGFR inhibitor gefitinib (Iressa) to 16 months with gefitinib…

*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and study co-authors say that “osimertinib has the potential to become a…

*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information. The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to be given in combo with JNJ-372 drug or separately and is/or…

*September 2019*  by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought we were all set with EGFR, suddenly we have some disruptive information that challenges how we're going to treat patients with EGFR-mutated cancers. At the American Society of Clinical Oncology…

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is once a patient develops resistance to an EGFR TKI. Two abstracts…

*October 2019*  by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to the development of novel targeted treatments in the frontline setting as well as expanding options for those with progressive disease, explained Timothy F. Burns, MD,…

*October 2018*  by Shalmali Pal Medpage Today and ASCO   Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early 2018 when it was named the "Advance of the Year" in the ASCO Annual Report. Versions of CAR-T cell therapy have shown promise for extending survival in previously incurable forms…